StockData
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31

Edwards Lifesciences Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$87.22+0.62 (+0.72%)

Close on Oct 19, 2026

Market cap
$50.38B
P/E (TTM)
50.1
Dividend yield
–

Earnings

Next report expected Oct 29, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 23, 2026After market close$1.74B$0.42$0.78
Q1 FY2026
Ended Mar 31, 2026
Apr 23, 2026After market close$1.65B$0.66$0.78
Q4 FY2025
Ended Dec 31, 2025
Feb 10, 2026After market close$1.57B$0.11$0.58
Q3 FY2025
Ended Sep 30, 2025
Oct 30, 2025After market close$1.55B$0.50$0.67
Q2 FY2025
Ended Jun 30, 2025
Jul 24, 2025After market close$1.53B$0.57$0.67
Q1 FY2025
Ended Mar 31, 2025
Apr 23, 2025After market close$1.41B$0.62$0.64
Q4 FY2024
Ended Dec 31, 2024
Feb 11, 2025After market close$1.39B$0.58$0.59
Q3 FY2024
Ended Sep 30, 2024
Oct 24, 2024After market close$1.35B$5.13$0.67
Q2 FY2024
Ended Jun 30, 2024
Jul 24, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
Apr 25, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Feb 6, 2024After market close–––

Company guidance

Outlook given with results on Jul 23, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
adjusted EPSnon-GAAPthird quarter of 2026$0.71 to $0.77New
adjusted EPSnon-GAAP2026$2.95 to $3.05Maintained
gross profit marginnon-GAAPfull-year 202678% to 79%Maintained
operating profit marginnon-GAAP202628% to 29%New
effective tax rate, excluding special itemsnon-GAAP202616% to 19%New
R&D expense as a percentage of sales202617%Maintained
TAVR salesfull-year 2026$4.75B to $5.00BLowered
total company salesfull-year 2026$6.60B to $6.90BRaised
TMTT salesfull-year 2026$760.00M to $780.00MLowered
total salesthird quarter of 2026$1.63B to $1.71BNew
TAVR constant currency sales growthnon-GAAPfull-year 20268% to 9% growthLowered
total company constant currency sales growthnon-GAAPfull-year 202610% to 11% growthRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Edwards Lifesciences filed with the SEC